Amphotericin B Plasma Monitoring for One Burn Child Using High-Performance Liquid Chromatography

Show simple item record

dc.contributor Sistema FMUSP-HC: Faculdade de Medicina da Universidade de São Paulo (FMUSP) e Hospital das Clínicas da FMUSP
dc.contributor.author SANCHES-GIRAUD, Cristina
GOMEZ, David S. FMUSP-HC
CAMPOS, Edvaldo V.
AZEVEDO, Rodrigo P. de FMUSP-HC
DESPINOY, Alessandra FMUSP-HC
PEREZ, Grazziela S.
FERREIRA, Marcus C. FMUSP-HC
SANTOS, Silvia R. C. J.
dc.date.issued 2011
dc.identifier.citation LATIN AMERICAN JOURNAL OF PHARMACY, v.30, n.8, p.1468-1474, 2011
dc.identifier.issn 0326-2383
dc.identifier.uri http://observatorio.fm.usp.br/handle/OPI/22455
dc.description.abstract A bioanalytical micromethod was described for the quantification of amphotericin B in plasma by HPLC. The method showed high absolute recovery, good linearity (0.1-10.0 mu g/mL, r(2) = 0.999), sensitivity (limits of quantification: 0.1 mu g/mL), and acceptable stability. Inter/intraday precisions were 6.8 %/23 % and mean accuracy was 94.3 %. The method was applied to plasma monitoring of one burn child, 3 years old, 25 kg, thermal injury (18 % total burn surface area - TBSA). Amphotericin B (1 mg/kg) was prescribed from 24(tg) to 35(tg) day of the accident and plasma monitoring and pharmacokinetics was performed by serial blood collections on 274 and 354 days post burn. Plasma concentrations obtained were respectively 0.7 mu g/mL and 1.2 mu g/mL. Pharmacokinetics at both periods (27(tg) vs 35(tg) day) also was compared: 13.8 vs 14.3 h (t(1/2 beta)); 0.5 vs 03 mL/min.kg (CL(T)) and 0.65 vs 038 L/kg (Vd(ss)). In conclusion, drug plasma monitoring by HPLC was quite useful to guarantee low risk and drug efficacy in a paediatric burn patient.
dc.description.sponsorship · CAPES
· CNPq
· FAPESP
dc.language.iso eng
dc.publisher COLEGIO FARMACEUTICOS PROVINCIA DE BUENOS AIRES
dc.relation.ispartof Latin American Journal of Pharmacy
dc.rights restrictedAccess
dc.subject Amphotericin B; Burn child; Drug plasma monitoring; HPLC-UV; Pharmacokinetics
dc.subject.other internal standard; malignant diseases; human-serum; pharmacokinetics; assay; pharmacodynamics; extraction
dc.title Amphotericin B Plasma Monitoring for One Burn Child Using High-Performance Liquid Chromatography
dc.type article
dc.rights.holder Copyright COLEGIO FARMACEUTICOS PROVINCIA DE BUENOS AIRES
dc.description.group LIM/04
dc.type.category original article
dc.type.version publishedVersion
hcfmusp.author GOMEZ, David S.:HC:ICHC
hcfmusp.author AZEVEDO, Rodrigo P. de:HC:ICHC
hcfmusp.author DESPINOY, Alessandra:HC:ICHC
hcfmusp.author FERREIRA, Marcus C.:FM:MCG
hcfmusp.author.external · SANCHES-GIRAUD, Cristina:Univ Sao Paulo, Fac Pharmaceut Sci, Sao Paulo, Brazil
· CAMPOS, Edvaldo V.:Univ Sao Paulo, Hosp Clin, Fac Med, BR-05508 Sao Paulo, Brazil
· PEREZ, Grazziela S.:Univ Sao Paulo, Fac Pharmaceut Sci, Sao Paulo, Brazil
· SANTOS, Silvia R. C. J.:Univ Sao Paulo, Fac Pharmaceut Sci, Sao Paulo, Brazil
hcfmusp.origem.id WOS:000298869100002
hcfmusp.origem.id 2-s2.0-84856266693
hcfmusp.publisher.city LA PLATA
hcfmusp.publisher.country ARGENTINA
hcfmusp.relation.reference · Italia JL, 2009, ANAL CHIM ACTA, V634, P110, DOI 10.1016/j.aca.2008.12.006
· Watt K, 2011, EARLY HUM DEV, V87, pS61, DOI 10.1016/j.earlhumdev.2011.01.014
· Espada R, 2008, BIOMED CHROMATOGR, V22, P402, DOI 10.1002/bmc.947
· GALLIS HA, 1990, REV INFECT DIS, V12, P308
· Andes D, 2006, INFECT DIS CLIN N AM, V20, P679, DOI 10.1016/j.idc.2006.06.007
· Blanchet B, 2008, CLIN PHARMACOKINET, V47, P635, DOI 10.2165/00003088-200847100-00002
· BENSON JM, 1989, ANTIMICROB AGENTS CH, V33, P1989
· Nath CE, 2001, BRIT J CLIN PHARMACO, V52, P671, DOI 10.1046/j.0306-5251.2001.01496.x
· Eldem T, 2001, J PHARMACEUT BIOMED, V25, P53, DOI 10.1016/S0731-7085(00)00499-4
· Antachopoulos C, 2006, J CLIN MICROBIOL, V44, P553, DOI 10.1128/JCM.44.2.553-560.2006
· BACH PR, 1984, ANTIMICROB AGENTS CH, V26, P314
· Catalan Mercedes, 2006, Revista Iberoamericana de Micologia, V23, P39
· Cleary JD, 2007, J ANTIMICROB CHEMOTH, V60, P1331, DOI 10.1093/jac/dkm322
· Echevarria I, 1998, J CHROMATOGR A, V819, P171, DOI 10.1016/S0021-9673(98)00425-7
· Egger P, 2001, J CHROMATOGR B, V760, P307, DOI 10.1016/S0378-4347(01)00292-4
· FDA Home page, 2008, GUID IND BIOAN METH
· GRANICH GG, 1986, ANTIMICROB AGENTS CH, V29, P584
· Guszecki W.I, 2002, FEBS LETT, V524, P92
· HOSOTSUBO H, 1988, ANTIMICROB AGENTS CH, V32, P1103
· HOSOTSUBO H, 1989, J PHARMACEUT BIOMED, V7, P975, DOI 10.1016/0731-7085(89)80022-6
· Lambros MP, 1996, J CHROMATOGR B, V685, P135
· LopezGalera R, 1995, J CHROMATOGR B, V674, P298, DOI 10.1016/0378-4347(95)00322-3
· Nath CE, 2007, CHEMOTHERAPY, V53, P142, DOI 10.1159/000100013
dc.description.index WoS
hcfmusp.citation.scopus 0
hcfmusp.citation.wos 0
hcfmusp.affiliation.country Brasil


Files in this item

Files Size Format View

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record

Search DSpace



Browse

My Account

Statistics